Friday, November 08, 2013 by Proactive Investors
Immuron Limited (ASX: IMC) is set to trade higher after receiving investigational new drug clearance from the US Food and Drug Administration to commence a clinical trial of its bovine colostrum-derived therapeutic for the treatment of a liver disease, alcoholic steatohepatitis, or ASH.
Immuron is also in preparation for Phase IIb clinical trials of non-alcoholic steatohepatitis, or NASH.
Notably, the principal investigator for its NASH trial has been awarded a National Institutes of Health grant to conduct a clinical trial for ASH.\
This trial will be conducted by the TREAT consortium, one of the world’s leading collaborations for clinical research into fatty liver diseases.
TREAT consortium's ASH trial is expected to provide Immuron with additional guidance for its NASH trials commencing next year.
NASH and ASH arise from different causes; both result in liver damage potentially leading to liver fibrosis, liver cirrhosis hepatic carcinoma.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.